ABOS Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Benzinga - Mentions: ICU CYCN POAI PSTV ...

12 Health Care Stocks Moving In Thursday's Intraday Session

2 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

2 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

3 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

3 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

3 months ago - By: Benzinga

Acumen Pharmaceuticals's Earnings: A Preview

3 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

3 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

3 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025

3 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

6 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

6 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

6 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

6 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

6 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

6 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

7 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

7 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

7 months ago - By: Climb Bio, Inc. - Mentions: CLYM LENZ SLDB VERV

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

7 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

7 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

7 months ago - By: Acumen Pharmaceuticals, Inc.